Oral dydrogesterone in frozen-thawed embryo transfer cycles
Rev. Assoc. Med. Bras. (1992)
;
68(1): 100-105, Jan. 2022. tab, graf
Article
in English
| LILACS
| ID: biblio-1360701
ABSTRACT
SUMMARY OBJECTIVE:
The aim of this study was to compare the use of micronized vaginal progesterone and oral dydrogesterone in the endometrial preparation for frozen-thawed embryo transfer.METHODS:
This was a randomized, controlled, open, two-armed clinical trial, with women undergoing frozen-thawed embryo transfer along with hormone replacement therapy for endometrial preparation, between September 2019 and February 2021. A total of 73 patients were randomly selected and orally administered 40 mg/day dydrogesterone (dydrogesterone group, n=36) or 800 mg/day micronized vaginal progesterone (micronized vaginal progesterone group, n=37), after endometrial preparation with transdermal estradiol. The main outcome was a viable ongoing pregnancy with 12 weeks of gestation as evaluated by ultrasound.RESULTS:
The reproductive outcomes in frozen-thawed embryo transfer cycles were similar, with pregnancy rates in the dydrogesterone and micronized vaginal progesterone treatment groups being, respectively, 33.3 and 32.4% at 12 weeks pregnancy (confidence interval= -22.4-20.6, p=0.196).CONCLUSIONS:
The use of oral dydrogesterone may be a more patient-friendly approach to endometrial preparation in frozen-thawed embryo transfer cycles, avoiding undesirable side effects and discomfort resulting from vaginal administration, while also providing similar reproductive results.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Dydrogesterone
/
Luteal Phase
Type of study:
Controlled clinical trial
Limits:
Female
/
Humans
/
Pregnancy
Language:
English
Journal:
Rev. Assoc. Med. Bras. (1992)
Year:
2022
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Centro de Referência da Saúde da Mulher Hospital Pérola Byington/BR
/
Irmandade da Santa Casa de Misericórdia de São Paulo/BR
Similar
MEDLINE
...
LILACS
LIS